New Therapy Silences Hepatitis B for 6+ Months in Mice

Millions of people take daily pills to keep hepatitis B in check, but scientists just found a way to potentially silence the virus for months with just three shots.

Researchers at nChroma Bio developed an experimental therapy that tags hepatitis B virus genes with a chemical "off switch" instead of cutting them out. In mice, three monthly doses kept about 90% of animals virus-free for at least six months after their final injection.

The approach targets hepatitis B's sneakiest survival trick. Even when antiviral pills suppress the virus, its DNA hides in two stubborn forms inside liver cells. One form sits like a tiny chromosome that constantly churns out new viruses. The other burrows into the host's own genome and pumps out viral proteins that train the immune system to ignore the infection.

Stop taking daily medication, and the virus roars back in nearly everyone. Over time, this cycle of dormancy and reactivation scars the liver and dramatically increases cancer risk, even before symptoms appear.

The new treatment works like nature's own gene control system. It delivers a modified version of CRISPR (stripped of its cutting ability) along with an enzyme that adds chemical tags to viral DNA. These tags flip genes off without destroying them, potentially avoiding collateral damage to healthy cells.

A single dose in mice reduced viral activity more than a thousandfold. Safety tests in monkeys found no major side effects or dangerous immune reactions. The highest doses did stress liver cells slightly, but researchers are still analyzing those results.

Why This Inspires

This matters beyond hepatitis B. The same epigenetic silencing approach could work on other viruses that hide in our DNA, from HIV to the chickenpox virus that causes shingles decades later.

The team stopped short of calling it a cure, but if the therapy proves safe and effective in humans, millions could swap daily pills for a few injections per year. Earlier this year, the first patient received the treatment in a Phase 1/2 clinical trial testing safety and early results.

Traditional antivirals are like constantly bailing water from a leaky boat. This new approach could finally patch the holes.